These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 16417239)

  • 1. Increased expression of CTLA-4 in malignant T-cells from patients with mycosis fungoides -- cutaneous T cell lymphoma.
    Wong HK; Wilson AJ; Gibson HM; Hafner MS; Hedgcock CJ; Berger CL; Edelson RL; Lim HW
    J Invest Dermatol; 2006 Jan; 126(1):212-9. PubMed ID: 16417239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spatiotemporal changes and functional alterations of T-cell substates gene expression during the progression of mycosis fungoides.
    Dong Z; Zhu X; Pan X; Su Q; Wang F
    Arch Dermatol Res; 2024 May; 316(6):207. PubMed ID: 38787417
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeting exhausted cytotoxic T cells through CTLA-4 inhibition promotes elimination of neoplastic cells in human myelofibrosis xenografts.
    Tavernari L; Rontauroli S; Norfo R; Mirabile M; Maccaferri M; Mora B; Genovese E; Parenti S; Carretta C; Bianchi E; Bertesi M; Pedrazzi F; Tenedini E; Martinelli S; Bochicchio MT; Guglielmelli P; Potenza L; Lucchesi A; Passamonti F; Tagliafico E; Luppi M; Vannucchi AM; Manfredini R;
    Am J Hematol; 2024 Jul; ():. PubMed ID: 38953347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CTLA-4: a moving target in immunotherapy.
    Rowshanravan B; Halliday N; Sansom DM
    Blood; 2018 Jan; 131(1):58-67. PubMed ID: 29118008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic predisposition to early mycosis fungoides: investigating genetic polymorphisms in tissue-resident memory T-cell genes.
    Almaani N; Farhan F; Bani Hamad S; Abuhawileh EA; Koubaitary L; Ahram M; Aladily TN
    J Int Med Res; 2024 Mar; 52(3):3000605241239034. PubMed ID: 38546260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pneumocystis jirovecii Pneumonia in a Patient With Localized Mycosis Fungoides Not Receiving Immunosuppressive Treatment.
    Kudoh R; Komiya K; Takaki R; Yokoyama A; Hiramatsu K; Kadota JI
    Cureus; 2024 Jan; 16(1):e51724. PubMed ID: 38318593
    [No Abstract]   [Full Text] [Related]  

  • 7. Differential Response of Mycosis Fungoides Cells to Vorinostat.
    Bordeaux ZA; Reddy SV; Lee K; Lu W; Choi J; Miller M; Roberts C; Pollizzi A; Kwatra SG; Kwatra MM
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of immune checkpoint receptors in the malignant phenotype of cutaneous T cell lymphoma.
    Shreberk-Hassidim R; Geiger-Maor A; Eisenberg G; Merims S; Hajaj E; Cohen JE; Klein S; Frankenburg S; Moyal L; Hodak E; Zlotogorski A; Lotem M
    Immunol Res; 2022 Dec; 70(6):793-799. PubMed ID: 35867216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mass Cytometric Analysis of Early-Stage Mycosis Fungoides.
    Guo N; Jia L; Out-Luiting C; Miranda NFCC; Willemze R; Koning F; Vermeer M; Quint K
    Cells; 2022 Mar; 11(7):. PubMed ID: 35406628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantifying protein abundance on single cells using split-pool sequencing on DNA-barcoded antibodies for diagnostic applications.
    Sheng J; Hod EA; Vlad G; Chavez A
    Sci Rep; 2022 Jan; 12(1):884. PubMed ID: 35042926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normal and cancer fibroblasts differentially regulate TWIST1, TOX and cytokine gene expression in cutaneous T-cell lymphoma.
    Mehdi SJ; Moerman-Herzog A; Wong HK
    BMC Cancer; 2021 May; 21(1):492. PubMed ID: 33941102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradication.
    Durgin JS; Weiner DM; Wysocka M; Rook AH
    J Am Acad Dermatol; 2021 Mar; 84(3):587-595. PubMed ID: 33352267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas.
    Neuwelt A; Al-Juhaishi T; Davila E; Haverkos B
    Blood Adv; 2020 Sep; 4(17):4256-4266. PubMed ID: 32898250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycosis fungoides associated with recurrence of malignant melanoma.
    Bhat TS; Rosman IS; Cornelius LA; Musiek AC
    JAAD Case Rep; 2020 Aug; 6(8):793-795. PubMed ID: 32775589
    [No Abstract]   [Full Text] [Related]  

  • 15. Update on Biology of Cutaneous T-Cell Lymphoma.
    Phyo ZH; Shanbhag S; Rozati S
    Front Oncol; 2020; 10():765. PubMed ID: 32477957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitors to treat cutaneous malignancies.
    Barrios DM; Do MH; Phillips GS; Postow MA; Akaike T; Nghiem P; Lacouture ME
    J Am Acad Dermatol; 2020 Nov; 83(5):1239-1253. PubMed ID: 32461079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal Antibodies in Dermatooncology-State of the Art and Future Perspectives.
    Bobrowicz M; Zagozdzon R; Domagala J; Vasconcelos-Berg R; Guenova E; Winiarska M
    Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31554169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune targets in the tumor microenvironment treated by radiotherapy.
    Ozpiskin OM; Zhang L; Li JJ
    Theranostics; 2019; 9(5):1215-1231. PubMed ID: 30867826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma.
    Fujii K
    Front Oncol; 2018; 8():198. PubMed ID: 29915722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoint Inhibitors to Treat Malignant Lymphomas.
    Witkowska M; Smolewski P
    J Immunol Res; 2018; 2018():1982423. PubMed ID: 29850620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.